Last reviewed · How we verify
Diazepam Tablets
Diazepam enhances the inhibitory effects of GABA at GABA-A receptors in the central nervous system, reducing neuronal excitability.
Diazepam enhances the inhibitory effects of GABA at GABA-A receptors in the central nervous system, reducing neuronal excitability. Used for Anxiety disorders, Muscle spasms and spasticity, Seizure disorders and status epilepticus.
At a glance
| Generic name | Diazepam Tablets |
|---|---|
| Sponsor | Queen Sirikit National Institute of Child Health |
| Drug class | Benzodiazepine |
| Target | GABA-A receptor |
| Modality | Small molecule |
| Therapeutic area | Neurology, Psychiatry |
| Phase | FDA-approved |
Mechanism of action
Diazepam is a benzodiazepine that binds allosterically to GABA-A receptors, potentiating the effect of the inhibitory neurotransmitter GABA. This results in increased chloride ion influx into neurons, leading to hyperpolarization and reduced firing. The drug produces anxiolytic, sedative, muscle relaxant, and anticonvulsant effects through this mechanism.
Approved indications
- Anxiety disorders
- Muscle spasms and spasticity
- Seizure disorders and status epilepticus
- Alcohol withdrawal syndrome
- Insomnia
Common side effects
- Drowsiness and sedation
- Dizziness
- Ataxia and impaired coordination
- Dependence and withdrawal
- Cognitive impairment
- Respiratory depression
Key clinical trials
- Sunitinib or Cediranib for Alveolar Soft Part Sarcoma (PHASE2)
- Efficacy of Ketorolac for Postoperative Pain Management in Hip Arthroscopy: A Prospective Double-Blinded Randomized Controlled Trial (PHASE4)
- Clinical Efficacy of Diazepam After Whiplash (PHASE4)
- Vaginal Diazepam for the Treatment of Female Pelvic Pain (PHASE2)
- Investigating the Role of Diazepam on Brain Function and Chemistry in Psychosis Risk (NA)
- Rectal Versus Oral Diazepam Administration in the Treatment of Levator Ani Syndrome (PHASE4)
- Efficacy of Hydroxyzine for Patients With Panic Disorder (PHASE4)
- Oral Olanzapine Versus Haloperidol or Diazepam (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Diazepam Tablets CI brief — competitive landscape report
- Diazepam Tablets updates RSS · CI watch RSS
- Queen Sirikit National Institute of Child Health portfolio CI